Monday, August 31, 2026
ExploreSearch
Via News
MarketIndexes

NASDAQ 100 Went Down By Over 3% In The Last 5 Sessions

ViaNews Editorial Team

September 6, 2024

NASDAQ 100 Went Down By Over 3% In The Last 5 Sessions

(VIANEWS) - NASDAQ 100 (NDX) has been up by 3.09% for the last 5 sessions. At 10:11 EST on Friday, 6 September, NASDAQ 100 (NDX) is $18,728.80.

Volume

Today's last reported volume for NASDAQ 100 is 224525910, 90.2% below its average volume of 2291990668.99.

Concerning NASDAQ 100's yearly highs and lows, it's 33.22% up from its 52-week low and 9.48% down from its 52-week high.

News about

  • S&P 500, nasdaq, asx: elliott wave analysis & trade strategy for global market indices. According to FXStreet on Wednesday, 4 September, "While the S&P 500 and NASDAQ 100 have different tops for Wave (1), we anticipate Wave (2) to complete simultaneously across the SP500, DAX 40, FTSE 100, and ASX 200. ", "Video Chapters 00:00 SP 500 (SPX) 10:03 NASDAQ (NDX) 11:35 Russell 2000 (RUT) IWM ETF 12:42 DAX 40 (DAX) 19:00 FTSE 100 UKX (UK100) 20:20 S&P/ASX 200 (XJO) 22:41 End"

More news about NASDAQ 100 (NDX).

Categories

MarketIndexes

Tags

IndexWorld IndicesIndicesNDXNASDAQ 100Price DownINDICES Price DownIndex Now
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com